Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b PK and safety of single-dose rFXIII in young children with congenital FXIII A-subunit deficiency
2009-016869-28Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jul 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of catridecacog in Factor XIII A subunit deficiency, sponsored by Novo Nordisk. Primary endpoint: Area under the concentration vs. time curve (AUC 0–30 Days). Started Jul 2010; status: completed.
02
Drugs
catridecacog
03
Conditions
Factor XIII A subunit deficiency
Beyond the preview
Go deeper on 2009-016869-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016869-28.